Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.46 |
| ▸ | IDH1 | O75874 | 5/20 | 0.38 |
| ▸ | IDH2 | P48735 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803797 | 0.77 | ADORA2A (0.34) | — | |
| SCHEMBL3295825 | 0.74 | MALT1 (0.47) | MALT1IDH1IDH2TAS2R14 | |
| SCHEMBL21328933 | 0.74 | MALT1 (0.52) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL29757680 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL19337822 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL19063 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL19582176 | 0.73 | MALT1 (0.50) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL1420222 | 0.73 | NOS3 (0.47) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL18428 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 | |
| SCHEMBL2632680 | 0.73 | MALT1 (0.46) | MALT1IDH1IDH2NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4598923-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | The Regents of the University of California (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-3703692-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230172-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| EP-4061813-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4511127-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025006078-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-2121661-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2112880-A2 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2009-11-04 | — | — | EP | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008076243-A2 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076243-A2 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| CN-1135227-C | 2,6-twice substituted pyridine and 2,4-twice substituted pyrimidine for berbicide | 谷 | 2004-01-21 | — | — | CN | disclosed |
| CN-1117748-C | Herbicidal 2, 6 -disubstituted pyridines and 2, 4 -disubstituted pyrimidines | AMERICAN CYANAMID CO (US) | 2003-08-13 | — | — | CN | disclosed |
| CN-1175578-A | Herbicidal 2, 6 -disubstituted pyridines and 2, 4 -disubstituted pyrimidines | AMERICAN CYANAMID CO (US) | 1998-03-11 | — | — | CN | disclosed |
| CN-1143078-A | 2,6-twice substituted pyridine and 2,4-twice substituted pyrimidine for berbicide | AMERICAN CYANAMID CO (US) | 1997-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | MALT1 87/4885IDH1 34/4885IDH2 25/4885 |
| US-20240398781-A1 | SPIROCYCLIC CYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, PMP22, NR1H2 | MALT1 1489/4885IDH1 1994/4885IDH2 909/4885 |
| US-20250230172-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | MALT1 3795/4885IDH1 1480/4885IDH2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.